The FDA Just Approved a New Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

The FDA Just Approved a New Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy

According to a story from raredr.com, The U.S. Food and Drug Administration (FDA) has recently approved Hizentra as a maintenance therapy for patients with chronic inflammatory demyelinating polyneuropathy. Hizentra is…

Continue Reading
Close Menu